We keep our 12-month target at $146 on a below peers 1.1X PE-to-growth ratio based on our 2015
EPS estimate. Q1 EPS of $1.07 vs. $0.83 is $0.03 ahead of our estimate. However, sales growth,
including 2% adverse forex impact, of 20.2% was below our 22% growth forecast. Revlimid sales
rose 17%, Abraxane rose 21%, and Pomalyst/Imnovie rose 46%, but Vidaza sales fell 3% on
generic competition. We remain encouraged by the growth of Revlimid and believe further label
expansion will drive continued demand and we see Abraxane sales reaching $1B this year.
...very shareholder friendly mgmt. $7 billion cash on books and increasing, no debt
...got too much on downside.. actually this is good for long term health of stock..to shake out short term traders...as long as fundamentals intact..which i believe they are
all short term money is out...that got in Jan-Feb when BIIB was at this level.
I feel BIIB will stagnate between 370-400 till next earnings...
any opinion.. i am already long cost avg. around 280
u think 3% dividend makes for 15% loss of capital? stock has gone down from 114 to 96 despite strong economy and low fuel
its very old call . Jan2014...with $70..
celgene has come long way..9/10 analayst still recommend v. strong buy...
Yes, short for day or two....MM will take to $500..
it is best among the best sectors.. if u want to short go with speculatives that went up with rising tide..don;t short CELG.BIIB,GILD...